UCB
UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders (including epilepsy), inflammatory disorders (including allergy), and oncology.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Albuterol | Albuterol | 1992-09-29 | 2025-2041 | |
| Amitriptyline | Amitriptyline | 1982-01-01 | ||
| Bimzelx | Bimekizumab | 2023-10-17 | ||
| Biphetamine | Amphetamine, Dextroamphetamine | 1982-01-01 | 2024-2038 | |
| Briviact | Brivaracetam | 2016-05-12 | 2026-2030 | |
| Briviact (in italy: nubriveo) | Brivaracetam | 2016-01-13 | 2026-2030 |
1
2
3
4
>
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
1
2
3
4
5
6
7
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use